相关实验视频

Updated: Jul 25, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

模拟英国HIV-1中药物耐药性的出现和传播

Anna Zhukova¹, David Dunn², Olivier Gascuel³

¹Bioinformatics and Biostatistics Hub, Institut Pasteur, Université Paris Cité, 75015 Paris, France.

|June 28, 2023

概括

了解HIV-1药物耐药性突变 (DRM) 是改善治疗的关键. 这项研究开发了一种分析DRM传输和获取模式的新方法,揭示了突变类型和亚型之间的重要差异.

科学领域:

病毒学病毒学
流行病学流行病学
计算生物学计算生物学

背景情况:

了解HIV-1传播和耐药性对于有效的治疗策略至关重要.
获得和持久的HIV-1药物耐药性突变 (DRMs) 是复杂的,并且有很大的差异.
分析DRM模式的现有方法在范围和准确性方面存在局限性.

研究的目的:

开发和验证一种新的计算方法,用于估计HIV-1药物耐药性获得和传播模式.
分析大规模的HIV-1序列数据,以确定影响DRM动态的因素.
为了提供更准确的DRM逆转时间估计,并识别需要加强监测的突变.

主要方法:

开发一种最大概率的祖先特征重建方法.
将治疗推广日期纳入遗传学分析.
应用到来自英国艾滋病毒药物耐药性数据库的大数据集.

主要成果:

确定了多态和非多态DRM之间以及HIV-1亚型B和C之间DRM获取和传播模式的显著差异.
与以前的研究相比,提供了更准确的DRM逆转时间估计,信心区间更窄.
证明了大型阻力集群与多态DRM和那些损失时间长的DRM相关.
在英国观察到DRM的流行率下降,但相对于获得的耐药性突变,传染性耐药性的比例增加.

结论:

开发的方法提供了一个强大的方法来分析大型HIV-1序列数据集,以了解耐药性动态.
由于其持久性和传播模式,特定的DRM和耐药性集群需要有针对性的监测.
虽然DRM的总体患病率可能会下降,但传染性耐药性的比例越来越高,凸显了持续监测和干预的必要性.

关键词:

艾滋病病毒-1 艾滋病病毒-1 祖先的性格重建的重建药物耐药性突变药物耐药性突变

更多相关视频

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

相关概念视频

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...